| Primary |
| Iron Overload |
33.0% |
| Thalassaemia Beta |
22.0% |
| Sickle Cell Anaemia |
7.3% |
| Myelodysplastic Syndrome |
6.4% |
| Zygomycosis |
5.5% |
| Acute Myeloid Leukaemia |
4.6% |
| Chelation Therapy |
4.6% |
| Haemochromatosis |
2.8% |
| Serum Ferritin Increased |
2.8% |
| Anaemia |
1.8% |
| Acute Monocytic Leukaemia |
0.9% |
| Aplastic Anaemia |
0.9% |
| Graft Versus Host Disease |
0.9% |
| Hereditary Haemochromatosis |
0.9% |
| Hypertension |
0.9% |
| Hypothyroidism |
0.9% |
| Lymphoma |
0.9% |
| Myelofibrosis |
0.9% |
| Pain |
0.9% |
| Prophylaxis |
0.9% |
|
| Vomiting |
16.7% |
| Serum Ferritin Increased |
11.1% |
| Nephrolithiasis |
9.3% |
| Proteinuria |
9.3% |
| Death |
7.4% |
| Nausea |
5.6% |
| Blood Urea Increased |
3.7% |
| Creatinine Renal Clearance Decreased |
3.7% |
| Hepatic Enzyme Increased |
3.7% |
| Paraesthesia |
3.7% |
| Thrombocytopenia |
3.7% |
| Upper Gastrointestinal Haemorrhage |
3.7% |
| Weight Increased |
3.7% |
| Zygomycosis |
3.7% |
| Abdominal Distension |
1.9% |
| Abdominal Pain |
1.9% |
| Alanine Aminotransferase Increased |
1.9% |
| Aortic Aneurysm Rupture |
1.9% |
| Blindness |
1.9% |
| Blood Bilirubin Increased |
1.9% |
|
| Secondary |
| Iron Overload |
20.9% |
| Helicobacter Infection |
18.0% |
| Thalassaemia Beta |
13.4% |
| Aplastic Anaemia |
5.8% |
| Myelodysplastic Syndrome |
5.8% |
| Prophylaxis |
5.8% |
| Chelation Therapy |
5.2% |
| Product Used For Unknown Indication |
3.5% |
| Acute Myeloid Leukaemia |
2.3% |
| Antifungal Prophylaxis |
2.3% |
| Drug Use For Unknown Indication |
2.3% |
| Neutropenia |
2.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.3% |
| Zygomycosis |
2.3% |
| Sickle Cell Anaemia |
1.7% |
| Acute Monocytic Leukaemia |
1.2% |
| Antibiotic Prophylaxis |
1.2% |
| Campylobacter Infection |
1.2% |
| Helicobacter Pylori Infection |
1.2% |
| Osteoporosis |
1.2% |
|
| Vomiting |
22.6% |
| Serum Ferritin Increased |
21.0% |
| Acute Myeloid Leukaemia |
6.5% |
| Pyrexia |
6.5% |
| Glycosuria |
4.8% |
| Transaminases Increased |
4.8% |
| Cholecystitis |
3.2% |
| Leukocytoclastic Vasculitis |
3.2% |
| Pancreatitis |
3.2% |
| Paraesthesia |
3.2% |
| Peripheral Sensory Neuropathy |
3.2% |
| Sudden Death |
3.2% |
| Weight Increased |
3.2% |
| Aspartate Aminotransferase Increased |
1.6% |
| Asthenia |
1.6% |
| Cardiac Siderosis |
1.6% |
| Fatigue |
1.6% |
| Growth Hormone Deficiency |
1.6% |
| Headache |
1.6% |
| Hepatic Neoplasm Malignant |
1.6% |
|
| Concomitant |
| Prophylaxis |
20.1% |
| Aplastic Anaemia |
18.3% |
| Product Used For Unknown Indication |
9.5% |
| Infection Prophylaxis |
8.9% |
| Premedication |
6.9% |
| Bone Marrow Conditioning Regimen |
4.1% |
| Iron Overload |
3.9% |
| Chronic Obstructive Pulmonary Disease |
3.4% |
| Myelodysplastic Syndrome |
3.0% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.7% |
| Prophylaxis Against Graft Versus Host Disease |
2.7% |
| Osteoporosis |
2.6% |
| Acute Myeloid Leukaemia |
2.1% |
| Constipation |
2.1% |
| Sickle Cell Anaemia |
2.0% |
| Antifungal Prophylaxis |
1.8% |
| Hypertension |
1.7% |
| Antiviral Prophylaxis |
1.6% |
| Gastritis Prophylaxis |
1.3% |
| Insomnia |
1.3% |
|
| Pneumonia |
14.1% |
| Therapeutic Response Decreased |
8.2% |
| Lung Squamous Cell Carcinoma Stage Unspecified |
7.1% |
| Neutropenia |
7.1% |
| White Blood Cell Count Decreased |
7.1% |
| Sickle Cell Anaemia With Crisis |
5.9% |
| Death |
4.7% |
| Febrile Neutropenia |
4.7% |
| Lung Squamous Cell Carcinoma Stage 0 |
4.7% |
| Pyrexia |
4.7% |
| Thrombocytopenia |
4.7% |
| Sepsis |
3.5% |
| Transfusion Reaction |
3.5% |
| Tumour Lysis Syndrome |
3.5% |
| Vomiting |
3.5% |
| White Blood Cell Count Increased |
3.5% |
| Abdominal Pain Upper |
2.4% |
| Cachexia |
2.4% |
| Cystitis Haemorrhagic |
2.4% |
| Diarrhoea |
2.4% |
|
| Interacting |
|
| Renal Failure Acute |
100.0% |
|
